This morning’s transactions show buyers paying for control over the scarce layer: food-processing capacity and port access in Mozambique, proprietary credit data in London, and a drug programme before its clinical value is settled. Where ownership is not yet agreed, governance is already part of the price.
Helios buys into Mozambique’s food-processing platform
Helios Fund V agreed to acquire up to 49% of Stratton Africa Holdings, the Mauritius-incorporated owner of Mozambique’s Merec Industries, from Invictus Investment. Invictus will remain the majority shareholder, and consideration was not disclosed. Merec’s footprint across Beira, Maputo and Nacala gives the partnership a physical platform for expansion; shareholder rights, capex and regional sequencing will determine how far it travels.
Dangote owns part of the route to market
Dangote Industries acquired 25% of Kenya Pipeline Company for a reported US$335 million and outlined a separate US$1.5 billion network expansion plan. The ownership is complete as reported; the expansion is not. The stake ties a planned Lamu refinery to an existing distribution route, making access terms, tariffs, capacity and minority governance part of the refinery economics.
LSEG pays for proprietary credit intelligence
LSEG agreed to buy credit-data provider Octus for US$3.54 billion, financing the acquisition with external debt. Octus is expected to generate US$300–320 million of revenue this year. The attraction is hard-to-replicate data built inside a professional workflow; the integration challenge is to widen distribution without weakening the data-production engine.
Gilead pays upfront for an early clinical option
Gilead agreed to pay US$1.275 billion upfront for PepStar Therapeutics’ HCXT-2001 inflammation programme and worldwide rights. The candidate remains in early-stage testing with no published clinical data. That puts unusual weight on diligence, clinical stage gates and the discipline to stop, combine or accelerate as evidence develops.
SpaceX-Tesla puts governance ahead of structure
SpaceX and Tesla have formed special committees to examine a possible combination reportedly valued around US$3.5 trillion, but discussions remain early and no structure is agreed. Elon Musk’s roles and ownership in both companies make committee independence, valuation evidence and minority-shareholder treatment central to whether any proposal can withstand scrutiny.
Anthropic tests whether the IPO window is company-specific
Anthropic is reported to be preparing to market an IPO in the week of 9 November after making its prospectus public as early as late October. The dates may change and the offering has not launched. With other AI issuers delaying, the transaction will test whether scarcity and strategic position can overcome higher funding costs and concern about the durability of AI spending.
What the structure tells us
Africa’s transactions place ownership beside physical operating reach. Helios is buying influence over a food platform that already touches three port regions; Dangote has bought into the route that can carry refinery output. In both, the value moves only when shareholder rights and capital plans become operating decisions.
The global transactions pay for scarcity in data, science and market access, but the unresolved deals are a useful counterpoint. A valuation does not make a combination executable; independent process, evidence and timing do. That is why 0to1 follows the transaction rather than only the headline.
transactions · minority investment · food processing · infrastructure · data · biopharma · governance · IPO